anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Siponimod
Trial phase: Phase 1
ATC code: L04AA42 | L04AE03
SMILES: CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Treatment with a single oral dose of 0.25 mg BAF312
Eligibility criteria:
Inclusion Criteria:

All subjects:

Male and female Caucasian subjects 18 to 70 years of age
At least 50 kg and body mass index (BMI) within 18-35 kg/m2.
CYP2C9 wild-type (CYP2C9*1 homozygous carriers)

Hepatic impairment:

- Subjects must have either mild, moderate or severe hepatic impairment

Exclusion Criteria:

All subjects

Hepatic impairment due to non-liver disease.
Use of other investigational drugs within certain timelines
Donation or loss of 400 mL or more of blood or plasma within eight (8) weeks prior to initial dosing
History of cardiac rhythm abnormalities or cardiac rhythm abnormalities identified in the 24-h Holter ECG recording including episodes of bradycardia (HR < 50 bpm) during waking hours and/or arrhythmic episodes; subjects with history or presence of ventricular rhythm disturbances (ventricular extra-systoles >100/24h, or higher grade), or supraventricular arrhythmias (other than occasional supraventricular ectopic beats with a maximum of 5 subsequent ectopic beats per event) or subjects with conduction disturbances (higher than AV-block grade 1) or bradycardia or tachycardia.
History of cardiac catheter ablation.
Women of child-bearing potential
History of malignancy of any organ system
Recent and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease)
History or presence of symptomatic postural hypotension or syncope.
Total WBC or lymphocyte counts which falls outside the 1.5-fold local laboratory normal range or platelet count < 30,000/μL at screening or baseline.
Clinically significant infection or recent vaccination with live-attenuated vaccines.
History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening.
History or presence of coronary heart disease (stable or unstable), myocardial infarction, myocarditis, cardiomyopathy, heart failure NYHA II - IV.

Hepatic impairment:

History or presence of any non-controlled and clinically significant disease that could affect the study outcome or that would place the patient at undue risk.
Any surgical or medical condition other than hepatic impairment which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the study subject in case of participation in the study.
Treatment with certain drugs

Healthy subjects:

History or presence of any clinically significant disease of any major system organ class including (but not limited to) cardiovascular, metabolic, renal, neurological or psychiatric diseases.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, drugs, or which may jeopardize the subject in case of participation in the study.
Intervention: Metformin
Trial phase: Not Applicable
ATC code: A10BA02 | A10BD02 | A10BD03 | A10BD05 | A10BD07 | A10BD08 | A10BD10 | A10BD11 | A10BD13 | A10BD14 | A10BD15 | A10BD16 | A10BD17 | A10BD18 | A10BD20 | A10BD22 | A10BD23 | A10BD25 | A10BD26 | A10BD27
SMILES: CN(C)C(=N)NC(=N)N
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Metformin at 500 mg PO BID and pending lab values may have been titrated to 1000 mg PO BID at 1 month.
Eligibility criteria:
Inclusion Criteria:

symptomatic HF of any etiology
age ≥ 18 years
fasting blood sugar equal or greater than 100 mg/dL, or pre-DM (HbA1c 5.7 - 6.4%) or early DM (HbA1c ≥ 6.5%)

Exclusion Criteria:

current metformin therapy or other anti-diabetic therapy
previous intolerance to metformin therapy
renal dysfunction (Cr >1.5 in men or > 1.4 in women or creatinine clearance < 60 ml/minute)
history of lactic acidosis
current or planned pregnancy or breast-feeding
Intervention: Metformin
Trial phase: Phase 2
ATC code: A10BA02 | A10BD02 | A10BD03 | A10BD05 | A10BD07 | A10BD08 | A10BD10 | A10BD11 | A10BD13 | A10BD14 | A10BD15 | A10BD16 | A10BD17 | A10BD18 | A10BD20 | A10BD22 | A10BD23 | A10BD25 | A10BD26 | A10BD27
SMILES: CN(C)C(=N)NC(=N)N
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Metformin: Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.

Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy.
Eligibility criteria:
Inclusion Criteria:

Patients with potential diagnosis of ovarian, fallopian, or primary peritoneal cancer.
Care plan including surgical debulking and traditional adjuvant or neo-adjuvant chemotherapy (6-9 cycles of platinum and taxane based therapy).
Eastern Cooperative Oncology Group performance status 0-2.
Age > 18 years or < 80 years.
Adequate renal function (serum creatinine <1.4mg/dL).

Adequate liver function (bilirubin < 1.5 times ULN).

Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) < 5 times the upper limit of normal in case of liver metastases.
ALT or AST < 2.5 times the ULN in absence of liver metastases.
Ability to understand and complete written informed consent.
Mentally, physically, and geographically able to undergo treatment and follow up.

Exclusion Criteria:

Patients diabetes mellitus. (Patients with only a history of gestational diabetes will be allowed to be included in the study.)
Metformin use in the last 6 months.
A known hypersensitivity to metformin.
A history of metabolic acidosis, including ketoacidosis or increased risk of lactic acidosis.
Pregnancy or Lactation.
Patients who have any severe and/or uncontrolled medical conditions.
Patients with a history of renal disease.
Patients with other known active malignancy (excluding adequately treated basal cell / squamous cell skin cancer, in situ cancer, or other cancer for which the patient has been disease free for 2 years).
Patients receiving any other investigational agents.
Intervention: Riboflavin
Trial phase: Phase 1 | Phase 2
ATC code: A11HA04 | S01XA26
SMILES: Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: The donor cornea used as a carrier for the Boston Keratoprosthesis underwent crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.

Riboflavin: Used to treat donor cornea before implantation
Eligibility criteria:
Inclusion Criteria:

Ability to provide written informed consent and comply with study assessments for the full duration of the study.
Age > 18 years.
A negative urine pregnancy test.
Candidate for a Boston Keratoprosthesis/Corneal transplant.
Generally good stable overall health.

Patients with an eye at risk for a cornea sterile ulcer which includes:

Chemical injuries.
Autoimmune diseases (ocular cicatricial pemphigoid, Stevens Johnson Syndrome, systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune diseases).
History of previous sterile corneal ulceration requiring a cornea transplant.

Exclusion Criteria:

Age < 18 years.
Inability to provide written informed consent and comply with study assessments for the full duration of the study.
Pregnant or lactating women.
No or minimal tear production.
Ocular or periocular malignancy.
Inability to wear a contact lens due to lid abnormalities or shortened fornix.
Signs of current infection, including fever and current treatment with antibiotics.
Participation in another simultaneous medical investigation or trial
Intervention: Capecitabine
Trial phase: Phase 1
ATC code: L01BC06
SMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.

capecitabine: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Eligibility criteria:
Inclusion Criteria:

rectal adenocarcinoma, clinical stage II/III(T3-4 or N+, AJCC 7th).
KPS status no less than 70; Charlson comorbidity no more than 3.
life expectancy more than 6 months.
hemoglobin >= 100g/L, white blood cell >= 3.5*10E9/L, neutrophil >= 1.5*10E9/L, platelet >= 100*10E9/L.Creatin normal, Total bilirubin normal, AST and AST normal, AKP normal.
do not have allergy history to thymidine phosphorylase.
do not receive surgery ( except palliative colostomy) or chemotherapy or other anti-cancer treatment
no previously pelvic irradiation history
informed consent signed

Exclusion Criteria:

other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma
previous pelvic irradiation history
receiving surgery (except palliative colostomy), chemotherapy or other anti-cancer treatment
allergy history to thymidine phosphorylase
active infection existed
severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia， etc.
anticipate other clinical trials in four weeks before enrollment
Intervention: Capecitabine
Trial phase: Phase 1
ATC code: L01BC06
SMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.

Capecitabine: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Eligibility criteria:
Inclusion Criteria:

rectal adenocarcinoma, clinical stage II/III(T3-4 or N+, AJCC 7th).
KPS status no less than 70; Charlson comorbidity no more than 3.
life expectancy more than 6 months.
hemoglobin >= 100g/L, white blood cell >= 3.5*10E9/L, neutrophil >= 1.5*10E9/L, platelet >= 100*10E9/L.Creatin normal, Total bilirubin normal, AST and AST normal, AKP normal.
do not have allergy history to thymidine phosphorylase.
do not receive surgery ( except palliative colostomy) or chemotherapy or other anti-cancer treatment
no previously pelvic irradiation history
informed consent signed

Exclusion Criteria:

other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma
previous pelvic irradiation history
receiving surgery (except palliative colostomy), chemotherapy or other anti-cancer treatment
allergy history to thymidine phosphorylase
active infection existed
severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia， etc.
anticipate other clinical trials in four weeks before enrollment
Intervention: Capecitabine
Trial phase: Phase 1
ATC code: L01BC06
SMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.

Capecitabine: oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Eligibility criteria:
Inclusion Criteria:

rectal adenocarcinoma, clinical stage II/III(T3-4 or N+, AJCC 7th).
KPS status no less than 70; Charlson comorbidity no more than 3.
life expectancy more than 6 months.
hemoglobin >= 100g/L, white blood cell >= 3.5*10E9/L, neutrophil >= 1.5*10E9/L, platelet >= 100*10E9/L.Creatin normal, Total bilirubin normal, AST and AST normal, AKP normal.
do not have allergy history to thymidine phosphorylase.
do not receive surgery ( except palliative colostomy) or chemotherapy or other anti-cancer treatment
no previously pelvic irradiation history
informed consent signed

Exclusion Criteria:

other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma
previous pelvic irradiation history
receiving surgery (except palliative colostomy), chemotherapy or other anti-cancer treatment
allergy history to thymidine phosphorylase
active infection existed
severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia， etc.
anticipate other clinical trials in four weeks before enrollment
Intervention: Capecitabine
Trial phase: Phase 1
ATC code: L01BC06
SMILES: CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.

Capecitabine: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Eligibility criteria:
Inclusion Criteria:

rectal adenocarcinoma, clinical stage II/III(T3-4 or N+, AJCC 7th).
KPS status no less than 70; Charlson comorbidity no more than 3.
life expectancy more than 6 months.
hemoglobin >= 100g/L, white blood cell >= 3.5*10E9/L, neutrophil >= 1.5*10E9/L, platelet >= 100*10E9/L.Creatin normal, Total bilirubin normal, AST and AST normal, AKP normal.
do not have allergy history to thymidine phosphorylase.
do not receive surgery ( except palliative colostomy) or chemotherapy or other anti-cancer treatment
no previously pelvic irradiation history
informed consent signed

Exclusion Criteria:

other cancer history, except curable non-melanoma skin cancer or cervix in-situ carcinoma
previous pelvic irradiation history
receiving surgery (except palliative colostomy), chemotherapy or other anti-cancer treatment
allergy history to thymidine phosphorylase
active infection existed
severe complication, such as acute myocardial infarction in 6 months, uncontrolled diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe cardiac arrhythmia， etc.
anticipate other clinical trials in four weeks before enrollment
Intervention: Finasteride
Trial phase: Phase 2
ATC code: D11AX10 | G04CA51 | G04CA55 | G04CB01 | G04CB51
SMILES: [H][C@@]12CC[C@@]3([H])NC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](C(=O)NC(C)(C)C)CC[C@@]21[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.

Finasteride: Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
Eligibility criteria:
INCLUSION CRITERIA:

Participant must have chronic Central Serous Chorioretinopathy (CSC) in at least one eye as defined by all of the following criteria. This eye will be referred to as the study eye.
The presence of subretinal fluid, as determined by optical coherence tomography (OCT), AND
The subretinal fluid must have been present for at least three months or recurrent in cases of chronic CSC/diffuse retinal pigment epitheliopathy, AND/OR
The presence of characteristic fluorescein angiographic or autofluorescence features of CSC, such as one or more pinpoint leaks and/or diffuse retinal pigment epitheliopathy noted on fluorescein or descending tract lesions on autofluorescence.
Participant must have a steady fixation in the study eye.
Participant must have media clear enough in the foveal or parafoveal area in the study eye for good quality photographs.
Participant must have visual acuity between 20/25 and 20/400 in the study eye.

EXCLUSION CRITERIA:

Participant has evidence of choroidal neovascularization (CNV) in the study eye.
Participant is expected to need ocular surgery in the study eye during the first three months of the study.
Participant has had photodynamic therapy (PDT) or focal laser treatment in the study eye within three months prior to enrollment or is expected to need PDT or focal laser treatment in the study eye during the first three months of the study.
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Half of the patients will be randomized to Vicodin

Acetaminophen: 325 mg
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older.
All subjects will be competent adults able to consent on their own behalf for surgery and care.
Inclusion prior to surgery
Carpal tunnel release

Exclusion Criteria:

Pregnant women. Patients will be queried with the routine preoperative medical history and an inclusion/exclusion checklist.
Patients unable to give informed consent
Non English-speaking subjects
Patients with hypersensitivity to acetaminophen or hydrocodone
Patients with chronic alcohol abuse
Patients with severe impairment of renal or hepatic function. This will be assessed in the routine preoperative medical history and review of the medical record. We will also ask the patients specific for this history in the screening for the study inclusion/exclusion criteria.
Patients with hypothyroidism
Patients with Addison's disease
Patients with prostatic hypertrophy or urethral stricture
Patients using any of the following medications:

MAO or tricyclic antidepressants Antihistaminics Antipsychotic or anti-anxiety medications Phenothiazines Zidovudin Phenobarbital

Patients who are taking opioid pain medication for another reason prior to surgery.
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: Half of the patients will be randomized to Acetaminophen

Vicodin: Vicodin 5/325 mg
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older.
All subjects will be competent adults able to consent on their own behalf for surgery and care.
Inclusion prior to surgery
Carpal tunnel release

Exclusion Criteria:

Pregnant women. Patients will be queried with the routine preoperative medical history and an inclusion/exclusion checklist.
Patients unable to give informed consent
Non English-speaking subjects
Patients with hypersensitivity to acetaminophen or hydrocodone
Patients with chronic alcohol abuse
Patients with severe impairment of renal or hepatic function. This will be assessed in the routine preoperative medical history and review of the medical record. We will also ask the patients specific for this history in the screening for the study inclusion/exclusion criteria.
Patients with hypothyroidism
Patients with Addison's disease
Patients with prostatic hypertrophy or urethral stricture
Patients using any of the following medications:

MAO or tricyclic antidepressants Antihistaminics Antipsychotic or anti-anxiety medications Phenothiazines Zidovudin Phenobarbital

Patients who are taking opioid pain medication for another reason prior to surgery.
Intervention: LITHIUM CARBONATE
Trial phase: Phase 4
SMILES: O=C([O-])[O-].[Li+].[Li+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 53
Group description: After a washout period of up to 1 week, subjects will be openly randomized to treatment Lithium for 2 weeks. Subjects who become intolerant to or Lithium at any point will be crossed over to the other mood stabilizer (Divalproex) and continued in the study. Adverse events were not collected for Randomization 2.
Eligibility criteria:
Inclusion Criteria:

DSM-IV TR (Diagnostic and Statistical Manual Edition IV Text Revision) diagnosis BD I or II as assessed by MINI PLUS (Mini International Neuropsychiatric Interview PLUS)
Male or female ≥ 18 years old
Currently symptomatic with a CGI-BP-S ≥3 for mania/hypomania &/or depression for ≥ 2 weeks
One of the following indicators of recent active illness: a depressive or manic or hypomanic or mixed episode in the past 12 months
If female of child bearing age must use effective birth control.

Exclusion Criteria:

Unwilling or unable to comply with study requirements
Renal impairment (serum creatinine > 1.5 mg/dL)
If maintained on thyroid medication must be euthyroid for at least 1 month before Visit 1
Patients who have had intolerable side effects to QTP, Li, Div, or LTG
Patients whose clinical status requires inpatient care
Drug/alcohol dependence within the past 30 days
Pregnancy as determined by serum pregnancy test or breastfeeding
History of poor response to Li at a serum Li of ≥ 0.5 mEq/L (milliequivalents per Liter) or Div at a serum level of ≥ 45 mg/dL for at least 2 weeks.
Intervention: Dasatinib
Trial phase: Phase 2
ATC code: L01EA02 | L01XE06
SMILES: Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 171
Group description: Dasatinib 100 mg tablet by mouth QD up to 60 months
Eligibility criteria:
Inclusion Criteria:

Chronic Phase (CP)-CML Ph+ patients with complete hematologic response (CHR) but without one log BCR-ABL reduction (BCR-ABL level >10% IS) 3 months of imatinib 400mg treatment. (Imatinib transient dose adjustments due to Adverse Event (AEs) are allowed with a maximum of 2 weeks interruption of treatment with imatinib (cumulative) within the 3 month period before randomization). Imatinib monotherapy must have been started within 6 months of CP-CML diagnosis (Ph + /BCR-ABL detection)
Currently tolerating imatinib 400mg QD. Patients with prior imatinib treatment interruption or dose reductions are required to be on treatment with 400 mg imatinib for two weeks immediately prior to randomization to ensure tolerance to imatinib
Eastern Co-Operative Group (ECOG) performance status = 0 - 2
Adequate renal function defined as serum creatinine ≤3 times the institutional upper limit of normal (ULN)
Adequate hepatic function defined as: total bilirubin ≤2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times the institutional ULN

Exclusion Criteria:

Previous diagnosis of accelerated phase or blast crisis
Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases at baseline bone marrow cytogenetic test, unless the same abnormalities were present at diagnosis. Patients with no evidence of clonal evolution, including those patients whose cytogenetic testing fails or bone marrow aspiration is a dry tap at 3 months, are eligible for the study
Subjects with less than CHR after 3 months of imatinib treatment or lost CHR after initial achievement
Documented T315I/A, F317L, or V299L mutations (if already available - not required for screening)
A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy